A Phase 1a/b Study Investigating the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of BGB-58067 an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors
Brief description of study
This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 as monotherapy in patients with advanced solid tumors.
Clinical Study Identifier: s25-00200
ClinicalTrials.gov Identifier: NCT06589596
Principal Investigator:
Kristen Spencer.
Other Investigators:
Caitlin Elizabeth Ordonez Ferri,
Elaine Shum,
Jessica Goggin,
Yoke Wah Khoo,
Kirby Rodriguez,
Manuel Hidalgo Medina,
Maya Dimitrova,
Mariam M Cheaib,
Salman Rafi Punekar,
Janice Mehnert,
Joshua K Sabari,
Keriann M Scavone,
Nina Beri,
Rajwanth Veluswamy,
Paul E. Oberstein,
Marissa Barbaro,
Eneil De La Pena,
Jose Ricardo McFaline Figueroa,
David R. Wise,
Jessica D. Schulte,
Jessica Wang,
Alexandra Gewirtz,
Neil L. Sielski,
Paige Gugerty,
Maria Francis,
Michelle Diane Swanson Lightfoot,
Zujun Li,
Minerva A Utate,
Alexandra M. Miller,
Jennifer H Fisher,
Kathleen M Madden,
Nancy Chan,
Bhavana Pothuri,
Ruth A White,
Matthew A. Ingham,
Douglas K Marks.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
